Is Tandem Diabetes Care (TNDM) overvalued or fairly valued?

MarketChacha shows Tandem Diabetes Care's valuation in context — a forward P/E of about 148.5, a price-to-book of about 8.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Tandem Diabetes Care's revenue?

Tandem Diabetes Care reported revenue of $1.0B for FY2025, with net profit of $-204.7M, per official filings.

What is the share price of Tandem Diabetes Care (TNDM)?

Tandem Diabetes Care last traded at $16.89 (-4.0% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Tandem Diabetes Care

TNDM · NYSE · Healthcare · United States

$16.89-4.0%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:34 PM

Snapshot

TickerTNDM

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees2,500

HeadquartersSan Diego, United States

Market cap$1.2B

P/B8.7

Volume859.02K

Websitewww.tandemdiabetes.com

Filings tracked4

About Tandem Diabetes Care

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.0%
Institutions99.0%
Public & other0.0%

374 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.60%
Sessa Capital IM, L.P.6.90%
Vanguard Portfolio Management LLC5.83%
ArrowMark Colorado Holdings LLC4.53%
Vanguard Capital Management LLC4.43%
GW&K Investment Management, LLC3.92%
State Street Corporation3.88%
Driehaus Capital Management, LLC3.36%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -131.9% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-29.8% → -20.2%

Margin has expanded by about 9.6 points — the business is getting more profitable.

Return on equity-131.9%

Latest ROE of -131.9% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $268.4M · EPS -0.19

Est. earnings growth +38.9%

Next fiscal year

Rev $1.2B · EPS 0.11

Est. earnings growth +116.4%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$9.9852-wk range$29.65

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.2B

Day change

-4.0%

Fwd P/E

148.5

P/B

8.7

Beta

1.58

Revenue (FY2025)

$1.0B

Net margin

-20.2%

ROE

-131.9%

Revenue CAGR (2y)

+16.5%

EPS (FY2025)

-3.04

Net profit (FY2025)

$-204.7M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about TNDM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.0B	$-204.7M	-3.04	-20.2%	-131.9%
FY2024	$940.2M	$-96.0M	-1.47	-10.2%	-36.5%
FY2023	$747.7M	$-222.6M	-3.43	-29.8%	-71.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$247.2M	$-20.4M	-0.30	-8.2%
2025Q4	$290.4M	$-589,000	-0.01	-0.2%
2025Q3	$249.3M	$-21.2M	-0.31	-8.5%
2025Q2	$240.7M	$-52.4M	-0.78	-21.8%
2025Q1	$234.4M	$-130.6M	-1.97	-55.7%
2024Q4	$282.6M	$755,000	0.01	0.3%
2024Q3	$244.0M	$-23.3M	-0.35	-9.5%
2024Q2	$221.9M	$-30.8M	-0.47	-13.9%
2024Q1	$191.7M	$-42.7M	-0.65	-22.3%
2023Q4	$196.8M	$-30.0M	-0.46	-15.2%
2023Q3	$185.6M	$-33.0M	-0.51	-17.8%
2023Q2	$195.9M	$-35.8M	-0.55	-18.3%
2023Q1	$169.4M	$-123.9M	-1.92	-73.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Security holder rights, Executive/director change, Shareholder vote results, Exhibits
SEC5/21/2026material
8-K — Executive/director change
SEC5/15/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.